Notably, XZF treatment significantly decreases PD-1 expression in CD8+ T-cells, which may alleviate T-cell exhaustion and enhance antitumor activity, thereby improving the immune microenvironment within prostate cancer tissue. Here, PDCD1 is linked to prostate cancer.